This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Crown Bioscience, Inc. (Taicang). Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Jixian Li: Innovator in Cancer Research
Introduction
Jixian Li is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of cancer research, particularly in the development of methods for predicting the responsiveness of cancer cells to specific inhibitors.
Latest Patents
Jixian Li holds a patent titled "Methods for determining responsiveness to MEK/ERK inhibitors." This innovative method predicts the responsiveness of a cancer cell to an MEK inhibitor by detecting the presence of mutations in genes such as ADAM12, COL14A1, TNN, and TP53. The presence of these mutations indicates decreased responsiveness of the cancer cell to the ERK inhibitor, providing valuable insights for targeted cancer therapies. He has 1 patent to his name.
Career Highlights
Throughout his career, Jixian Li has worked with various organizations, including Crown Bioscience, Inc. and Crown Bioscience Inc. His work has focused on advancing cancer treatment methodologies and improving patient outcomes through innovative research.
Collaborations
Jixian Li has collaborated with esteemed colleagues such as Sheng Guo and Wubin Qian. These partnerships have contributed to the advancement of his research and the development of effective cancer treatment strategies.
Conclusion
Jixian Li's contributions to cancer research through his innovative patent and collaborations highlight his commitment to improving cancer treatment. His work continues to pave the way for advancements in the field, making a significant impact on patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile